NCT05170867 is a NA clinical trial of Hafnia alvei HA4597™ in Obesity, sponsored by Universidade Nova de Lisboa.

Who is sponsoring NCT05170867?

NCT05170867 is sponsored by Universidade Nova de Lisboa.

What drugs are being tested in NCT05170867?

Interventions in NCT05170867: Hafnia alvei HA4597™, Placebo.

What condition does NCT05170867 study?

NCT05170867 studies Obesity, Type 2 Diabetes.

Is NCT05170867 still recruiting?

NCT05170867 is currently active, enrolled. Last updated 9 May 2024.

Last reviewed 2024-05-09 · How we verify

NCT05170867

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Impact of Hafnia Alvei on Weight Loss and Glycaemic Control After Bariatric Surgery

Active, enrolled NA Last updated 9 May 2024

What this trial tests

NA trial testing Hafnia alvei HA4597™ in Obesity in 49 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

14 January 2022

Primary endpoint
31 May 2025

31 December 2025

Quick facts

Lead sponsor	Universidade Nova de Lisboa
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	49
Start date	14 January 2022
Primary completion	31 May 2025
Estimated completion	31 December 2025
Sites	1 location across Portugal

Drugs / interventions tested

Hafnia alvei HA4597™
Placebo

Conditions studied

Obesity — all drugs for Obesity →
Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Universidade Nova de Lisboa — full company profile →

Who can join

Adults 18 to 65, any sex, with Obesity or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the effects of Hafnia alvei HA4597 TM supplementation on weight loss and glycemic control after bariatric surgery. Patients undergoing Roux-en-Y gastric bypass will receive probiotics or placebo, twice a day, for 90 days, one month after surgery. Outcomes will be measured at baseline, and 3, 6, 9 and 12 months after the surgery.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives.
Vallianou NG, Kounatidis D, Tsilingiris D, Panagopoulos F, et al · · 2023 · cited 73× · PMID 37047729 · DOI 10.3390/ijms24076755
Exploring Therapeutic Advances: A Comprehensive Review of Intestinal Microbiota Modulators.
Pires L, González-Paramás AM, Heleno SA, Calhelha RC. · · 2024 · cited 13× · PMID 39200020 · DOI 10.3390/antibiotics13080720
The impact of Hafnia alvei HA4597™ on weight loss and glycaemic control after bariatric surgery - study protocol for a triple-blinded, blocked randomized, 12-month, parallel-group, placebo-controlled clinical trial.
Ismael S, Vaz C, Durão C, Silvestre MP, et al · · 2023 · cited 2× · PMID 37248499 · DOI 10.1186/s13063-023-07383-0

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Universidade Nova de Lisboa trials

Trials by the same sponsor.

NCT05593835 — Multimorbidity Management Supported by a Digital Platform · NA · not yet recruiting
NCT06794515 — cGMP: Metabolism and Appetite Modulation · NA · not yet recruiting
NCT05788952 — The Role of Intestinal and Vaginal Microbiota, Estrogenic Activity, Metabolic Profile & Nutritional Status in Endometrio · unknown
NCT05375487 — The Effect of Natural Carbonated Mineral Water Consumption on Gastrointestinal Transit and Gut Microbiota - A Randomized · NA · completed
NCT05840627 — Acute Satiety and Metabolic Response of Daily Consumption of a Fruit Juice · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05170867 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidade Nova de Lisboa
Last refreshed: 9 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05170867.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing